[The comparison in vitro the effects of pravastatin and quercetin on the selected structural parameters of membrane erythrocytes from patients with hypercholesterolemia].
The aim of the study was to compare the effects in vitro of pravastatin and quercetin on the structural parameters of erythrocyte membrane of patients with hypercholesterolemia type II.


METHODS
2% suspensions of erythrocytes from hypercholesterolemic patients (n = 30, mean age 54.2 +/- 6.9) and healthy donors (n = 22, mean age 53.1 +/- 6.1) were incubated for 24 hours at 37 degrees C with or without pravastatin (9 microM, 90 microM), quercetin (10 microM, 50 microM, 100 microM). After the incubation we assessed, the cholesterol content (by method of Ilcy), the level of TBARS (by method of Stocks and Dormandy), the membrane fluidity (by paramagnetic resonance).


RESULTS
In erythrocytes of patients (pts) with hypercholesterolemia type II (hip II) in comparison to the control group significantly higher mean values of membrane cholesterol content (0.065 +/- 0.013 vs 0.039 +/- 0.008AU, p < 0.001), the order parameter S (0.775 +/- 0.018 vs 0.752 +/- 0.018, p < 0.001) and TBARS level (2.91 +/- 1.01 vs 1.60 +/- 0.41 mmol/gHb, p < 0.001) were observed. After incubation of erythrocytes from hypercholesterolemic patients with pravastatin it was noticed the significant decrease (in dependence on statin concentration - 9 microM, 90 microM) of mean cholesterol content (by 23% and 37%, respectively) and the order parameter S (by 2% and 3%) in comparison the values after erythrocyte incubation without statin. Pravastatin didn't influence on the level of TBARS. After incubation with quercetin it was observed the significant decrease of membrane cholesterol (26-33%), the order parameter S (maximum by 4%) i TBARS levels (16-25%).


CONCLUSIONS
1. Pravastatin and quercetin, in vitro, in similar degree decrease the level of membrane cholesterol and advantageously influence on membrane fluidity of erythrocytes from patients with hypercholesterolemia type II. 2. Pravastatin, in vitro, in opposite to quercetin doesn't influence on lipid peroxidation in erythrocytes of patients with hypercholesterolemia type II and healthy.
Broncel
Marlena
M
Uniwersytet Medyczny w Lodzi, Klinika Chorób Wewnetrznych z Oddziałem Farmakologii Klinicznej i Terapii Monitorowanej. ttm@ttm.org.pl
Franiak
Ida
I
Koter-Michalak
Maria
M
Duchnowicz
Piotr
P
Chojnowska-Jezierska
Julita
J
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D004578:Electron Spin Resonance Spectroscopy; D004907:Erythrocyte Deformability / Q000187:drug effects; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood*; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects*; D008563:Membrane Lipids / Q000378:metabolism; D008875:Middle Aged; D017035:Pravastatin / Q000494:pharmacology*; D011794:Quercetin / Q000494:pharmacology*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000924:Anticholesteremic Agents; D000975:Antioxidants; D008563:Membrane Lipids; D017392:Thiobarbituric Acid Reactive Substances; D011794:Quercetin; D017035:Pravastatin